How could nanobiotechnology improve treatment outcomes of anti-TNF-alpha therapy in inflammatory bowel disease? Current knowledge, future directions

• Type: Another Publication in an International Scientific Journal
• Date: 2021

Authors

Eder, P (Author) Other; Zielinska, A (Author) Other; Karczewski, J (Author) Other; Dobrowolska, A (Author) Other; Slomski, R (Author) Other; Souto, EB (Author) Other

Journal

Title: Journal of Nanobiotechnology

Vol. 18

ISSN: 1477-3155

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00V-M63

DOI: 10.1186/s12951-021-01090-1

Abstract (EN): Despite significant advances in therapeutic possibilities for the treatment of inflammatory bowel disease (IBD) in recent years, there is still a big room for improvement. In particular, biological treatment can induce not only clinical remission but also mucosal healing of the gastrointestinal tract. Among these therapeutic molecules, anti-tumor necrosis factor-alpha (anti-TNF-alpha) antibodies were the first to revolutionize treatment algorithms in IBD. However, due to the parenteral route of administration and systemic mode of action, TNF-alpha blockers are characterised by high rates of immunogenicity-related loss of response and serious adverse events. Moreover, intravenous or subcutaneous therapy is not considered patient-friendly and requires occasional, direct contact with healthcare centres. To overcome these limitations, several attempts have been made to design oral pharmaceutical formulations of these molecules. It is hypothesized that oral anti-TNF-alpha antibodies therapy can directly provide a targeted and potent anti-inflammatory effect in the inflamed gastrointestinal tissues without significant systemic exposure, improving long-term treatment outcomes and safety. In this review, we discuss the current knowledge and future perspectives regarding different approaches made towards entering a new era of oral anti-TNF-alpha therapy, namely, the tailoring of biocompatible nanoparticles with anti-TNF-alpha antibodies for site-specific targeting to IBD. In particular, we discuss the latest concepts applying the achievements of nanotechnology-based drug design in this area.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14